7759.TWO SUNHAWK BIO
- Market cap
- TWD 3.51B
- P/E
- -
- P/B
- 9.21x
- ROE
- -36.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 7759.TWO undervalued?
Graham numberThe Graham number of SUNHAWK BIO cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SUNHAWK BIO fundamental analysis
No fundamental analysis for SUNHAWK BIO yet.
SUNHAWK BIO stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SUNHAWK BIO
Sunhawk Vision Biotech, Inc., a drug development company, engages in the research and development of children's myopia eye drops, dry eye drops, and other nucleic acid new drugs for the treatment of ocular surface diseases in Taiwan. The company develops SHJ002 eye drops, which have completed a Phase 2 clinical trial for the treatment of dry eye disease in adult patients and corneal erosion in patients with Sjogren's syndrome, as well as in a Phase 2 clinical trial for myopi…
Full company profileSUNHAWK BIO financial statements
SUNHAWK BIO annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 952K | 0.00 | 0.00 | - | - |
| Operating Income | -39.6M | -15.6M | -113M | -101M | -175M |
| EBITDA | - | -15.1M | -96.6M | -82.2M | -166M |
| Net Income | -39.1M | -15.2M | -25.1M | -87.9M | -172M |
| EPS | -0.56 | -0.22 | -0.36 | -1.25 | -2.46 |
| Balance Sheet | |||||
| Total Assets | 109M | 143M | 321M | 309M | 499M |
| Total Liabilities | 1.70M | 166K | 11.3M | 12.6M | 27.0M |
| Shareholders' Equity | 108M | 142M | 310M | 296M | 472M |
| Cash & Short-term Investments | 11.9M | 22.8M | 175M | 111M | 401M |
| Cash Flow | |||||
| Operating Cash Flow | -33.9M | -24.1M | -75.1M | -95.0M | -145M |
| Capital Expenditure | 0.00 | 0.00 | 3.32M | 1.06M | 415K |
| Free Cash Flow | -33.9M | -24.1M | -78.4M | -96.1M | -145M |
| Ratios | |||||
| ROE | -36.4% | -10.7% | -8.1% | -29.7% | -36.5% |
| ROA | -35.8% | -10.6% | -7.8% | -28.5% | -34.6% |
| Net Profit Margin | -4,109.2% | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SUNHAWK BIO dividends
SUNHAWK BIO has not paid dividends in the last 5 fiscal years.
Who owns SUNHAWK BIO
Ownership data of SUNHAWK BIO is not available yet.
SUNHAWK BIO company profile
- Company name
- SUNHAWK BIO
- Ticker
- 7759.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No.66, Sanchong Road, Taipei, Taiwan, 115602
- Phone
- 886 2 2711 4597
- Website
- sunhawkvision.com
About SUNHAWK BIO
Sunhawk Vision Biotech, Inc., a drug development company, engages in the research and development of children's myopia eye drops, dry eye drops, and other nucleic acid new drugs for the treatment of ocular surface diseases in Taiwan. The company develops SHJ002 eye drops, which have completed a Phase 2 clinical trial for the treatment of dry eye disease in adult patients and corneal erosion in patients with Sjogren's syndrome, as well as in a Phase 2 clinical trial for myopia control in young children. Sunhawk Vision Biotech, Inc. was founded in 2019 and is based in Taipei, Taiwan.
SUNHAWK BIO management
3- Dr. Suh-Hang JuoFounder, Chairman & GM
- Dr. Chung-Ling LiangFounder, VP, Chief Medical Officer & Director
- Mr. Hao-Yu LinVP, Accounting Supervisor & CFO